Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerBilling CodesProprietary Laboratory AnalysesCPT cpt-0226u-tru-immune-neutralizing-antibody-assay
    Ask Trek AI about this page

    CPT 0226U: Tru–Immune™ SARS–CoV–2 Neutralizing Antibody Test

    CPT code 0226U is a Proprietary Laboratory Analyses (PLA) code for the Tru–Immune™ test from GenScript® USA/Ethos Laboratories that measures the current neutralizing capacity of antibodies against SARS–CoV–2 in a blood sample; the service is a laboratory-based serologic neutralization assay (proprietary PLA test) typically performed in a reference or commercial laboratory setting and billed as a clinical laboratory service.

    For related coverage guidance, see recent payer policy updates: Minimal Residual Disease (MRD) Testing for Cancer, Biomarker Testing Mandate, Prenatal (Fetal) Diagnostic Testing.

    Customize your policy alerts

    Sign up for cpt 0226U policy alerts

    Get alerted when payer policies referencing 0226U are released or updated.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Table of contents

    Progress1 / 7

    Explore openpayer tools

    • Billing CodesCPT, HCPCS, DRG & more
    • Reimbursement RatesCommercial vs. Medicare rate reports
    • Facility ComparisonBeds, revenue & payer mix
    • ProvidersHospitals & facilities
    • PayersPlans & market footprint
    • Taxonomy CodesNUCC specialty codes
    • ModifiersCPT modifiers & usage
    • Prior AuthorizationPA policies by payer & drug
    • Timely FilingFiling deadlines by payer
    • Coverage CriteriaMedical necessity by payer
    • Payer ContactsClaims, PA & appeals contacts
    View all tools

    Clinical & Coding Specifications

    Clinical Context

    A typical patient is an adult or pediatric patient presenting for assessment of immune protection against SARS–CoV–2, either after recent vaccination, prior infection, or exposure, or when evaluating immune status before immunosuppressive therapy. The clinician orders the Tru–Immune™ neutralizing antibody test performed by Ethos Laboratories (GenScript® USA). A phlebotomy appointment is scheduled at an outpatient laboratory, hospital outpatient phlebotomy unit, or ambulatory clinic. A blood specimen (serum or plasma per lab instructions) is collected, labeled with patient identifiers, and shipped to Ethos Laboratories under required temperature and handling conditions.

    Laboratory processing includes receipt, accessioning, and performing the proprietary neutralization assay that quantifies antibody-mediated inhibition of SARS–CoV–2 spike protein–ACE2 interaction. Results are reported as a numeric neutralizing antibody level and interpretive comment about current neutralizing capacity. The result is routed to the ordering provider via the electronic health record or secure report; clinicians use the result for counseling on infection risk, need for booster vaccination, or managing immunosuppressed patients. Typical sites of service are outpatient laboratory, hospital outpatient, ambulatory clinic, or mobile phlebotomy services. Common clinical indications include post-vaccination immune assessment, evaluation after confirmed or suspected SARS–CoV–2 infection, assessment in immunocompromised patients, and pre-exposure risk evaluation for high-risk procedures or travel.

    Related CPT Codes

    CPT CodeDescriptionRelationship to This Procedure
    0260UMeasurement of SARS–CoV–2 neutralizing antibodies, semi-quantitative or quantitative; specific proprietary methodAlternative PLA neutralization assay; may be ordered by the same clinician or used by different labs as a comparable test.
    86413Severe acute respiratory syndrome coronavirus 2 (SARS–CoV–2) antigen or antibody detection by immunoassay, qualitative or semiquantitative; multiple typesCommon antibody immunoassay often ordered alongside neutralizing antibody testing for broader serostatus assessment.
    86769Antibody; severe acute respiratory syndrome coronavirus 2 (SARS–CoV–2)Commonly billed for SARS–CoV–2 antibody detection to document prior infection or vaccine response in conjunction with neutralization testing.
    36415Collection of venous blood by venipuncturePhlebotomy CPT for blood collection required before performing the proprietary laboratory neutralization assay.
    99000Handling and/or conveyance of specimen for transfer from physician's office to a laboratory (transportation)Billing for specimen transport when separate billing is required by payer; supports chain-of-custody and timely delivery for testing.

    Related Modifiers

    5 rows

    ModifierDescriptionWhen to Use
    26Modifier 26 (Professional Component) identifies and bills only the professional portion of a split service — the physician’s interpretation, report, and medical judgment — when the technical…- Use CPT Modifier -26 when you are billing only the professional component (PC) of a split‑bill eligible service—i.e., you performed the physician interpretation, medical judgment and prepared a…
    52Modifier ‑52 (Reduced Services) indicates that a service or procedure was partially reduced or omitted at the provider’s discretion, allowing reporting of the basic procedure number with a qualifier…- Use modifier -52 when a physician or qualified health professional electively reduces or omits part of a procedure or service (for example, performing fewer required views or omitting a portion of…
    53Modifier 53 (Discontinued Procedure) signals that a surgical or diagnostic service was begun by the physician but terminated because of extenuating circumstances that threatened the patient’s…- Use modifier -53 when a physician/qualified healthcare professional has started a surgical or diagnostic procedure (e.g., anesthesia administered, incision or scope insertion) and then discontinues…
    78CPT modifier -78 indicates an unplanned, related return to the operating or procedure room by the same provider during the global postoperative period. It is appended when treatment for a…- Use modifier -78 when an unplanned, related complication during the original procedure’s global postoperative period requires the patient to return to a formal operating or procedure room and the…
    P6Modifier P6 indicates a declared brain‑dead patient whose organs are being removed for donor purposes. It is part of the Anesthesia Physical Status Modifiers (P1–P6) and corresponds to ASA VI. The…- When to use: Append CPT modifier P6 to anesthesia codes in the 00100–01999 range when the anesthesia provider documents a declared brain‑dead patient whose organs are being removed for donor…

    Related Provider Taxonomies

    8 rows

    Taxonomy Code
    207Q00000X
    207L00000X
    207R00000X
    208000000X
    2081P0301X
    364SP0809X
    3336M0003X
    2085H0002X

    Related ICD-10-CM Codes

    29 rows

    ICD-10-CM CodeDescription
    B34.2Coronavirus infection, unspecified
    B97.29Other coronavirus as the cause of diseases classified elsewhere
    D68.9Coagulation defect, unspecified
    E78.5Hyperlipidemia, unspecified
    I10Essential (primary) hypertension
    J12.82Pneumonia due to coronavirus disease 2019
    J18.9Pneumonia, unspecified organism
    J80Acute respiratory distress syndrome
    J98.8Other specified respiratory disorders
    M32.9Systemic lupus erythematosus, unspecified

    Showing 1–10 of 29

    Related Payer Policy Updates

    Specialty: Genetic & Molecular Testing1 / 3

    10 rows

    PolicyPayerEffective Date
    Minimal Residual Disease (MRD) Testing for Cancerregence2027-01-01
    Biomarker Testing MandateBlue Cross Blue Shield - Rhode Island2027-01-01
    Prenatal (Fetal) Diagnostic TestingBlue Cross Blue Shield - Rhode Island2027-01-01
    Oral Cancer Screening and TestingOscar Health2027-01-01
    RTM Testing for Alpha-1 Antitrypsin DeficiencyOscar Health2027-01-01
    Cytochrome P450 Genotype-Guided Treatment Strategy Corporate Medical Policybcbsvermont2027-01-01
    Cytochrome P450 Genotypingblue cross blue shield - tennessee2026-12-31
    Polygenic Risk ScoreBlue Cross Blue Shield - Rhode Island2026-12-01
    Gene Expression Profiling for Cutaneous MelanomaBlue Cross Blue Shield - Rhode Island2026-12-01
    Genetic Variant Testing (Including Liquid Biopsy) for Targeted Treatment in Advanced Cancerblue_shield_of_california2026-11-01

    Related Codes

    CPT-0001U-PRECISETYPE-HEA-MULTIPLEX-RBC-ANTIGEN-GENOTYPING

    CPT 0001U: PreciseType HEA Erythrocyte Antigen Genotyping

    CPT-0002U-POLYPDX-URINE-METABOLOMIC-ASSAY-ADENOMATOUS-POLYP-RISK

    CPT 0002U: PolypDX™ Urine Metabolomic Risk Assay

    CPT-0003U-OVAR-A-NEXT-GENERATION-OVARIAN-CANCER-RISK-ASSAY

    CPT 0003U: Overa (MIA2G) Ovarian Cancer Risk Assay

    CPT-0005U-PROSTATE-EXOSOMEDX-INTELLISCORE-GENE-EXPRESSION-URINE-TEST

    CPT 0005U: ExosomeDx Prostate (IntelliScore) urine gene expression test

    CPT-0007U-TOXPROTECT-URINE-DRUG-SCREEN-WITH-DNA-AUTHENTICATION

    CPT 0007U: ToxProtect Urine Drug Screen With DNA Authentication

    CPT-0008U-H-PYLORI-ANTIBIOTIC-RESISTANCE-SEQUENCING-PANEL

    CPT 0008U: H. pylori Antibiotic Resistance Gene Panel

    CPT-0009U-DEPARRAY-HER2-FISH-TUMOR-CELL-ISOLATION

    CPT 0009U: DEPArray HER2 Tumor‑Cell Isolation with FISH Analysis

    CPT-0010U-BACTERIAL-TYPING-WHOLE-GENOME-SEQUENCING-MAYO-CLINIC

    CPT 0010U: Bacterial Typing by Whole Genome Sequencing, Mayo Clinic

    CPT-0011U-CORDANT-CORE-ALGORITHMIC-ORAL-FLUID-DRUG-TEST

    CPT 0011U: Oral Fluid Drug Test with Algorithmic Steady‑State Comparison

    CPT-0016U-BCR-ABL1-MAJOR-MINOR-FUSION-TRANSCRIPT-TESTING

    CPT 0016U: BCR–ABL1 Major and Minor Breakpoint Fusion Transcripts

    Showing 1–10 of 536

    • More pages

    Frequently Asked Questions

    References

    1. 1.CPT® Codes and Descriptions. AAPC. Retrieved Aug 11, 2026.Maintains the CPT code set's official descriptions and guidelines, licensed from the American Medical Association, used as the definitional source for CPT codes on this page.
    2. 2.HCPCS Quarterly Update. Centers for Medicare & Medicaid Services (CMS). Retrieved Aug 11, 2026.CMS's quarterly release of HCPCS Level II codes and short/long descriptors, the source for HCPCS code definitions and update history.
    3. 3.ICD-10-CM Full Code List. Centers for Medicare & Medicaid Services (CMS). Retrieved Aug 11, 2026.CMS's complete ICD-10-CM diagnosis code list, used to cross-reference diagnosis codes associated with this procedure or service.
    Published by

    Trek Health powers OpenPayer with a leading commercial payer intelligence platform, seamlessly converting fragmented payer data into actionable insights for provider organizations.

    Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.